Controversies in the treatment of prostate cancer with maximal androgen deprivation.
Publication
, Chapter
McLeod, DG; Moul, JW
April 1995
The concept of maximal androgen deprivation (MAD) has become the accepted therapy for metastatic prostate cancer. MAD is also under investigation as neoadjuvant therapy prior to radical prostatectomy and radiation therapy. Innovative new approaches, such as intermittent androgen deprivation and new combination therapies, will emerge over the next decade.
Duke Scholars
Publication Date
April 1995
Volume
4
Start / End Page
345 / 359
Related Subject Headings
- Receptors, Androgen
- Radiotherapy, Adjuvant
- Prostatic Neoplasms
- Prostatectomy
- Oncology & Carcinogenesis
- Neoplasm Recurrence, Local
- Male
- Humans
- Chemotherapy, Adjuvant
- Androgen Antagonists
Citation
APA
Chicago
ICMJE
MLA
NLM
McLeod, D. G., & Moul, J. W. (1995). Controversies in the treatment of prostate cancer with maximal androgen deprivation. (Vol. 4, pp. 345–359).
McLeod, D. G., and J. W. Moul. “Controversies in the treatment of prostate cancer with maximal androgen deprivation.,” 4:345–59, 1995.
McLeod DG, Moul JW. Controversies in the treatment of prostate cancer with maximal androgen deprivation. In 1995. p. 345–59.
McLeod, D. G., and J. W. Moul. Controversies in the treatment of prostate cancer with maximal androgen deprivation. Vol. 4, 1995, pp. 345–59.
McLeod DG, Moul JW. Controversies in the treatment of prostate cancer with maximal androgen deprivation. 1995. p. 345–359.
Publication Date
April 1995
Volume
4
Start / End Page
345 / 359
Related Subject Headings
- Receptors, Androgen
- Radiotherapy, Adjuvant
- Prostatic Neoplasms
- Prostatectomy
- Oncology & Carcinogenesis
- Neoplasm Recurrence, Local
- Male
- Humans
- Chemotherapy, Adjuvant
- Androgen Antagonists